Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorvotuzumab mertansine (IMGN901) plus carboplatin/etoposide in advanced solid tumors including extensive-stage small cell lung cancer
2010-022950-17Phase 2Completed
- Sponsor
- ImmunoGen
- Start
- Aug 2011
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lorvotuzumab mertansine in small cell lung cancer (SCLC), Nonhematologic neoplasms and cancer, sponsored by ImmunoGen. Primary endpoint: Progression-free survival. Started Aug 2011; status: completed.
02
Drugs
lorvotuzumab mertansine
03
Conditions
small cell lung cancer (SCLC)Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2010-022950-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022950-17.